Provided by Tiger Fintech (Singapore) Pte. Ltd.

Denali Therapeutics Inc.

16.44
+0.38002.37%
Post-market: 16.440.00000.00%19:43 EDT
Volume:1.12M
Turnover:18.58M
Market Cap:2.39B
PE:-6.40
High:16.97
Open:16.56
Low:16.21
Close:16.06
Loading ...

Denali Therapeutics Shares Down 8.3% Premarket After Co's ALS Drug Fails in Mid-to-Late Stage Trial

THOMSON REUTERS
·
07 Jan

U.S. Stocks to Watch: Nvidia, Micron, Uber, FuboTV, Aurora Innovation, Plug Power, Inari Medical, and More

Dow Jones
·
07 Jan

BTIG Keeps Their Buy Rating on Denali Therapeutics (DNLI)

TIPRANKS
·
07 Jan

Denali Therapeutics Initiated at Outperform by Baird

Dow Jones
·
07 Jan

U.S. RESEARCH ROUNDUP-CNX Resources, Inari Medical, Royal Gold

Reuters
·
07 Jan

Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS), Denali Therapeutics (DNLI) and Inspire Medical Systems (INSP)

TIPRANKS
·
07 Jan

Denali Therapeutics Inc : JP Morgan Cuts Target Price to $24 From $28

THOMSON REUTERS
·
07 Jan

Stifel likes Denali Therapeutics on weakness

TIPRANKS
·
07 Jan

Denali Therapeutics Shares Down 6.2% After the Bell; Denali Therapeutics ALS Drug Fails in Mid-Stage Trial

THOMSON REUTERS
·
07 Jan

Denali Therapeutics Trial of Potential ALS Treatment Misses Primary, Secondary Endpoints; Shares Fall After Hours

MT Newswires Live
·
07 Jan

Denali Therapeutics Says ALS Trial Didn't Meet Endpoints

Dow Jones
·
07 Jan

UPDATE 1-Denali Therapeutics' ALS drug fails in mid-to-late stage trial

Reuters
·
07 Jan

Denali Therapeutics announces HEALEY ALS trial regimen misses endpoints

TIPRANKS
·
07 Jan

Denali Therapeutics ALS drug fails in mid-stage trial

Reuters
·
07 Jan

Denali Therapeutics Inc - Study Did Not Meet Primary Endpoint of Slowing Disease Progression

THOMSON REUTERS
·
07 Jan

Denali Therapeutics Inc - Key Secondary Endpoints Not Statistically Different at Week 24

THOMSON REUTERS
·
07 Jan

Denali Therapeutics Inc - Dnl343 Found to Be Safe and Well Tolerated

THOMSON REUTERS
·
07 Jan

Denali Therapeutics Announces Topline Results for Regimen G Evaluating Eif2b Agonist Dnl343 in the Phase 2/3 Healey ALS Platform Trial

THOMSON REUTERS
·
07 Jan

Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

GlobeNewswire
·
07 Jan

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic

Benzinga
·
04 Jan